OMIP
OMIP-016: Characterization of antigen-responsive macaque and human T-cells
Article first published online: 26 NOV 2012
DOI: 10.1002/cyto.a.22233
Copyright © 2012 International Society for Advancement of Cytometry
Additional Information
How to Cite
Guenounou, S., Bosquet, N., Dembek, C. J., Le Grand, R. and Cosma, A. (2013), OMIP-016: Characterization of antigen-responsive macaque and human T-cells. Cytometry, 83A: 182–184. doi: 10.1002/cyto.a.22233
Publication History
- Issue published online: 28 JAN 2013
- Article first published online: 26 NOV 2012
- Manuscript Accepted: 29 OCT 2012
- Manuscript Revised: 24 OCT 2012
- Manuscript Received: 25 SEP 2012
Funded by
- Agence Nationale de Recherches sur le SIDA et les Hépatites Virales (ANRS, Paris, France); Grant sponsor: “Europrise” European network of excellence. Grant Number: LSHP-CT-2006-037611 European grant
- ADITEC European project. Grant Number: HEALTH.2011.1.4-4
- European IMI Joint Undertaking (IMI-JU) project entitled “Biomarkers For Enhanced Vaccine Safety” (BIOVACSAFE)
- Innovative Medicines Initiative Joint Undertaking (BioVacSafe project). Grant Number: 115308
- European Union's Seventh Framework Programme. Grant Number: FP7/2007-2013
- EFPIA
Keywords:
- intracellular cytokines;
- T cells;
- HIV;
- SIV;
- vaccines
Purpose and Appropriate Sample Types
- Top of page
- Purpose and Appropriate Sample Types
- Background
- Similarity to Published OMIPs
- Acknowledgements
- Literature Cited
- Supporting Information
The present panel was optimized to assess the quality and phenotype of antigen-specific CD4 and CD8 T cells in both cynomolgus macaques and humans. The use of an identical protocol for specimens collected in the two species allows for an immediate translation of research from the macaque model to humans. Our protocol works well with cryopreserved and freshly collected PBMC. Following the fixing and permeabilization procedure, we introduced a freezing step that breaks the experimental procedure and allows the shipment of freshly stimulated and permeabilized samples to facilities equipped with instruments able to measure ten distinct fluorescences. Our procedure is thus adapted to multicenter studies where stimulation is performed on fresh PBMC and flow cytometry acquisition is done in a centralized facility.
Background
- Top of page
- Purpose and Appropriate Sample Types
- Background
- Similarity to Published OMIPs
- Acknowledgements
- Literature Cited
- Supporting Information
Preclinical data generated in macaque models can be used to validate research hypotheses in humans. In the field of viral immunology, macaque models are used to study new vaccine formulations and therapies (1). To facilitate the translational process from the macaque model to humans, we developed an intracellular cytokine staining protocol in which all the procedures have been optimized in parallel using specimens collected from the two species. The optimization procedure started from a panel previously used for human samples (2). Antibodies were titrated simultaneously on macaque and human PBMC (Supporting Information Figs. 1–5).
Unlike similar OMIPs, anti MIP-1β and anti-CD154 antibodies were included in the panel. MIP-1β increases detection of CD8 T cell responses (2, 3) and CD154 expands the detection of antigen specific CD4 T lymphocytes to cells that do not necessarily express the cytokines included in the panel (Tables 1 and 2) (4). To our knowledge, the present OMIP validates for the first time the use of CD154 to characterize antigen specific CD4 T-cell responses in macaques (Supporting Information Fig. 4).
CD45RA was chosen to discriminate the antigen experienced cells with a terminally effector phenotype (CD45RA+ CCR7−) from memory and effector memory cells (CD45RA− CCR7+/−). The number of naïve T cells (CD45RA+ CCR7+) carrying a T cell receptor specific for a given antigen will be too low to be detected within the 5 h incubation time of the present protocol assuring that antigen activated CD45RA+ T cells are truly terminally effector cells.
Various antibody-conjugates were tested to select the brightest. As an example, the optimization of the TNF-α staining is shown in Supporting Information Fig. 6.
A blue-fluorescent reactive dye excited by the UV laser was used as live/dead cells discrimination marker leaving other channels free for the detection of functional, lineage and differentiation markers. The live/dead discrimination marker has not been included in a dump channel to precisely evaluate the quality of the sample in terms of living cells. This is of paramount importance when frozen samples are analyzed.
All antibodies were added in a unique staining step immediately after the post-fixation/permeabilization thawing procedure (Supporting Information Table 2). This experimental sequence allows for multicenter studies and storage of samples that can be simultaneously stained according to instrument accessibility.
| Purpose | Quality and phenotype of antigen-specific CD4 and CD8 T cells |
| Species | Cynomolgus macaque or Human |
| Cell types | Fresh or cryopreserved PBMCs |
| Cross reference | OMIP-005 and OMIP-009 |
| Specificity | Fluorochrome | Clone | Purpose |
|---|---|---|---|
| Dead Cells | Blue fluorescent dye | na | Viability |
| CD3 | APC-Cy7 | SP34-2 | Lineage |
| CD4 | PerCP-Cy5.5 | L200 | Lineage |
| CD8 | V500 | RPA-T8 | Lineage |
| CD45RA | PE-Cy7 | L48 | Memory/differentiation |
| CD154 | FITC | TRAP1 | CD4 T cell activation |
| MIP-1β | PE | D21-1351 | Function |
| IFN-γ | V450 | B27 | Function |
| TNF-α | Ax700 | MAb11 | Function |
| IL-2 | APC | MQ1-17H12 | Function |
Figure 1 shows the adopted gating strategy in a macaque sample and in Supporting Information Figure 9 a representative staining on human PBMC is shown. To avoid exclusion of any relevant cell that, following activation, might have downregulated the CD3 molecule, we adopted a special gating strategy where the CD3 marker is gated against all the possible activation markers. CD3+ cell gates are then combined using a Boolean operator “OR.” The same gating procedure is adopted to identify CD4+ and CD8+ cells.
Figure 1. Example of gating strategy and staining results on cynomolgus macaque PBMC stimulated with peptides spanning the SIV Gag protein p15. PBMC were obtained from a macaque infected with SIV mac251. A: Singlets are selected using a FSC-A versus FSC-H plot. Lymphocytes are then selected using a FSC-A versus SSC-A plot and subsequently live cells are selected using a live/dead cell discriminator. B: CD3+ cells are selected plotting the CD3-axis versus all the functional markers used in the protocol in order to detect potential CD3 downregulation. CD3+ cell gates are adapted to include functional positive cells that downregulate CD3. The CD3+ population is calculated combining all the gates shown in (B) using the Boolean operator “OR.” C: Similar to CD3 T cells, CD4+ cells are selected taking in account the CD4 downregulation. The CD8 gate in (D) was used to discriminate functional positive CD4 T cells with a downregulated CD4 from functional positive CD8. Total CD4+ cells are then obtained by gates in (C) combined by the operator “OR” and the exclusion of the CD8 cells identified in (D). E: Live lymphocytes expressing CD3 and CD4 are then analyzed according to the expression of five functional markers (CD154, MIP-1β, IFN-γ, TNF-α, and IL-2) and the differentiation marker CD45RA. Combination of axis was chosen to allow easy positioning of gates and optimal discrimination between positive and negative events. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

Similarity to Published OMIPs
- Top of page
- Purpose and Appropriate Sample Types
- Background
- Similarity to Published OMIPs
- Acknowledgements
- Literature Cited
- Supporting Information
This OMIP shares some similarity to OMIP-005 and OMIP-009. Our OMIP-016 can be used to simultaneously analyze macaque and human samples. It is more oriented to CD4 activation with the inclusion of CD154 and it includes a breaking point in the experimental procedure allowing multicenter setting.
Acknowledgements
- Top of page
- Purpose and Appropriate Sample Types
- Background
- Similarity to Published OMIPs
- Acknowledgements
- Literature Cited
- Supporting Information
The authors thank the staff of TIPIV and FlowCyTech core facilities of the Division of Immuno-Virology at CEA for excellent technical assistance. They also thank Prof. Johannes R. Bogner for the collection of human PBMC. The authors declare no conflict of interest.
Literature Cited
- Top of page
- Purpose and Appropriate Sample Types
- Background
- Similarity to Published OMIPs
- Acknowledgements
- Literature Cited
- Supporting Information
- 1, , . Monkeying around with HIV vaccines: Using rhesus macaques to define ‘gatekeepers’ for clinical trials. Nat Rev Immunol 2009; 9: 717–728.
- 2
- 3, , , , , , , , , , et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006; 107: 4781–4789.
- 4, , , , , , , . Direct access to CD4+ T cells specific for defined antigens according to CD154 expression. Nat Med 2005; 11: 1118–1124.
Supporting Information
- Top of page
- Purpose and Appropriate Sample Types
- Background
- Similarity to Published OMIPs
- Acknowledgements
- Literature Cited
- Supporting Information
Additional Supporting Information may be found in the online version of this article.
| Filename | Format | Size | Description |
|---|---|---|---|
| CYTO_22233_sm_SuppInfo.doc | 2507K | Supporting Information | |
| Online_Table1.xlsx | 16K | Supporting Information | |
| Online_Table2.xlsx | 15K | Supporting Information | |
| Online_Table3.xlsx | 13K | Supporting Information | |
| Online_Table4.xlsx | 14K | Supporting Information | |
| MIFlowCyt_Item-Checklist.doc | 44K | Supporting Information |
Please note: Wiley-Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

1552-4930/asset/olbannerleft.gif?v=1&s=cf6fcbfdc8ffa722551b71f8be0977b5b04db6ee)
1552-4930/asset/olbannerright.gif?v=1&s=6d0ba4e64946e5d9d4ebba4b8395a68bf324cd0b)
